Concepedia

Kelly Locke

KL

Statistics

Publications

4

Citations

932

H-Index

4

Active since

2015

Affiliations

GlaxoSmithKline (United Kingdom)(Current)

Molecular Discovery (United Kingdom)

Kelly Locke is an author at GlaxoSmithKline (United Kingdom) specializing in pharmacy, life sciences, and bromodomain inhibition.

Publications per year

2015–2020

4

Publications

4

Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation

Huw D. Lewis, John Liddle, Jim Coote et al. · Nature Chemical Biology · 2015 · 760 citations · Full text

, , +2

Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors

Emmanuel H. Demont, Chun‐wa Chung, Rebecca C. Furze et al. · Journal of Medicinal Chemistry · 2015 · 79 citations · Full text

, , +16

Novel role of SARM1 mediated axonal degeneration in the pathogenesis of rabies

Vinod Sundaramoorthy, Diane Green, Kelly Locke et al. · PLoS Pathogens · 2020 · 59 citations · Full text

, , +17

A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification

Paul Bamborough, Chun‐wa Chung, Emmanuel H. Demont et al. · Journal of Medicinal Chemistry · 2019 · 34 citations · Full text

, , +12

1–4 of 4